InvestorsHub Logo
Followers 2772
Posts 77901
Boards Moderated 1
Alias Born 05/10/2007

Re: dmlabuda post# 465

Saturday, 06/02/2012 9:40:50 PM

Saturday, June 02, 2012 9:40:50 PM

Post# of 1153
So nothing has changed except the courts granted their final ruling and PIP won the case. PIP was up 27% Friday while the DOW was down 290 points. So if your charts are telling you nothing here changed then I think your charts are not plugged in to reality or they took the day off Friday and missed the news. That could be the dumbest post I ever read on ihub wow.

Under the Court's ruling, once SIGA earns $40 million in "net profits," PharmAthene shall be paid fifty percent (50%) of all net profits for a period from the date of entry of the Court's final order until ten (10) years from "first commercial sale." First commercial sale shall be deemed to occur following initial delivery of and payment for Product. The Court also awarded PharmAthene $2.4 million to cover a portion of its legal fees and expert witness and other costs, along with interest at the legal rate from the date of the final order until payment is made.

In 2011, the Biomedical Advanced Research and Development Authority (BARDA) awarded SIGA a base contract for the initial procurement of 1.7 million treatment courses of ST-246. The five-year base contract award is valued at $433 million, of which approximately $412.5 million is for purchase of the product. In May 2011, SIGA estimated that if the government were to purchase an additional 12 million treatment courses of smallpox antiviral, as outlined in BARDA's "justification for other than full and open competition" notification, the total value for the current U.S. civilian market, including the initial base contract for 1.7 million courses of therapy, could be approximately $2.8 billion.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.